In contrast to our results, a recent large study in adult AML patients who were eligible for intensive therapy and had an NPM1 mutation showed improved RFS and reduced cumulative incidence of relapse in patients with CC genotype treated with GO during the induction phase [13]. Here, NPM1 is linked to acute myeloid leukemia.